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ANGIOPLASTY-  STENTS AND ATHERECTOMY,  
LASERS AND OTHER DEVICES 
Long-Term Follow-Up of  "Stent*l ike" (_< 30% 
Diametar Stanosis Post) Ang iop las ty :A  Case for 
Provis ional  Stenting 
Patrick W. Sarruys, Aida J. Azar, Ulrich Sigwart, Woffgang Rutsch, Peter De 
Jaegere, Ferdinand Klemenij, Pim de Feyfor, Paul van den Heuvel, 
P~ma=-6 de Bmyne, Victor Legrsnd, Mario-ang~le Morel on behalf of the 
Benaste~ group. Thoraxcentre, University Hospital Dijkzigt, Rotterdam; 
The Netherlands 
Since it is uncl~3r whether the improved 1 yr clinical and 6 ruth angiogrephic 
out~ma after ste~ implantation is th~ result of its scaffolding properties or 
the late effect of a larger initial dilatation of the stenoals, we evaluated the 
outcome following 'Stent.like' PTCA (n = 90) and compared itto the complete 
Stunt grOup (n = 259) and the patients with a QCA diameter stenosis post- 
stantlng (DS) < 30=/0 (n = 213). The study paputation comprised 516 pts with 
stable angina reedomised toeither elective Palmaz-~chatz stent implantation 
or balloon angioplaety (PTCA) in Benestent-1. 'Stent-like' PTCA was defined 
as PTCA pts with DS _< 39%, 35% of pts in the PTCA group had a DS 
_< 30% compared to ~7% in the Stent. The results were as follows: event, 
dead/mi/cabg/pfoa; success, pts with assigned therapy and no inhospital 
events; re~tenoSis, >_ 50°/= diameter stsnosis follow-up (fup) 
"Stent-like" PTCA Total Stent population Stent DS _< 30% 
(n = 90) (n = 259) (n = 213) 
Success 78 (87%) 225 (87%) 199 (93=/=) 
Mid at fiJp (mm) 1.84 ~ 0.52 1.82 =1= 0.64 1.84 4- 0.61 
Restenosis 14 (16°/o) 51 (22%) ~ (18o/'=) 
Evem free 69 (77%) 199 (77=/°) 169 (79=/0) 
In conclusion: Our data suggest hat 'Stent-like' PTCA result in a clinical and 
angiographic long-term outcome equivalent o stentiog, therefore a strategy 
of provisional stenting shoutd be pmspaCtively tasted on a population treated 
with balloon angioplasty with on-line QGA DS __% 30°/o post procedure. 
~ A  RandOmized, Clinical o f  Radiation Therapy Trial 
to Reduce Restanosis Fol lowing Coronary 
Stenting---Early Results 
Paul S. Teirstein, Vincent MaSSullo, Shirish Jani, Robert J. Russo, Richard 
A, Schetz, Stephen Steuterman, Nancy B. Morris, Prabhakar Tripuraneni. 
Scripps Clinic, La Jolla, CA 
The SCRIPPS (Scripps Coronary Radiation to Inhibit Proliferation Post- 
Stunting) trial is a double-blind, randomized •al that couples coronary stent 
implantation with ionizing radiation to treat beth the recoil and proliferative 
components of restenosis. To date, following stent placement, 30 patients 
with restenotic lesions have been randomized to receive either transcatheter 
iridium-192 or placebo, non-radioaCtive seeds. Target vessels included na- 
tive o0ronades (13 lesions) and vein grafts (17 lesions). The mean lesion 
length was 10.2 + 6.3 mm and mean reference vessel diameter was 3.0 
± 0.7 ram. Dosimetry was calculated using intravascutar ultrasound (IVUS) 
measurements ot the radiation source to internal elastic membrane (IEM) 
distance. Iridium dbbons were advanced into the stented regfon through a 
non-centered, 4 Fr catheter, Mean iridium-192 specific activity was 97,6 :l= 
29.2 mCi and mean dwell time was 36 :i: 7.0 min. Mean shortest distance 
between radiation source and IEM was 1.02 d: 0.16 mm resuldog in a mean 
maximum target dose of 2651 -4- 349 cGy. The mean longest distance be- 
tween the radiation source and the IEM was 3.3 ± 0,47 mm resulting in a 
mean minimum radiation dose of 732 ± 83 cGy. 
All 10ts are scheduled for 6-rnonth angio and IVUS exam. Pts with subse- 
quent restenosis are decoded and, if in placebo arm, crossed over to radiation 
therapy. With a mean follow-up of 2,8 months, 2 pts (both in placebo group) 
required reinterVention for recurrent restenosis. No other adverse events 
have occurred. 
Radiation therapy coupled with stunting can be performed without early 
adverse events. Long-term results will be presented. 
~ Final Results of  Phases II, III, IV and V of  Medtronic 
Wiktor  Stent Implantation Without Coumadin 
Joseph Elias, Jean Pierre Monassier, Didier Carrie, Khalife Khalife, 
Gilles Grollier, Thierry Labbe, Michel Hanssen, Jean Marc Boulenc, 
Gerard Laval. CH Mulhouse, France 
From Desembei' 1993 to september 1995, in 5 French institutions, 422 
patients were prospectively treated attar Wiktor stent implantation with Ticlo- 
pidine (250 rag/day), Aspldn (100 mg/day) for 1 month and LMWH for 4 
weeks in phase II (79 patients), 2 weeks in phase Iti (96 patients), 1 week in 
phase IV (65 patients) and there was no LMWH in phase V (182 patients). 
Indications for stenting were: 
Phase II Phase ill Phase IV Phase V 
Suboptimal resu;1 56% 46% 40% 46% 
First intention 14% 26% 30% 38% 
Restenosis 18% 16O/o 2(R.~ 13% 
Bail OUt 12% 12% I(P/o 3% 
Must patients (92%) received 1 Stent, 6% recelvc~ 2 and 2'=/0 received 3. 
Results: 
Phase II Phase III Ph~Lse IV Phztse V 
Procedural success 97% 9~Y= ~ 3 -'/@ 97.5% 
Stent occlusion 1.36% 1% 1.5% 1% 
Death 1.36% 0% 0% 0% 
Emet0ency CABG 1.36% 1% 0% 0% 
Vx complications 1.36% 1% 1-5% 0% 
ConClusion: these data suggest that with a ~ Implantation technique, 
post Wiklor storing treatroent with Ticlopidine and Aspidn seems to reduce 
in Hospital major complications, additional treatment with LMWH does not 
seem beneficial. 
CARDIAC PACING 
~ FJectromagnetic Fi lters Impede Adverse 
interference o f  Pacemakers by Digital Cel lular 
Telephones 
Roger G. Card,o, Donald B. Williams, Ernest A. Tread, John S. Schor. 
Mount Sinai Medical Center, Miami Beach, FL 
Recent reports suggest that cr~jitat cellular telephones may adversely inter- 
fore with pacemaker function. The purpose of this study was to determine if 
electromagnetic filters in pacemakers impede interference from digital cellu- 
lar telephones. 
Sixty-fwe patients with permanent pacemakers from four different manu- 
facturers were studied (175 tests) D'mital cel!ular tel .ephnnes were nlacecl in 
dose proximity (1-5 crn) to the pulse generator during continuous electrocar- 
diographic monitoring. Adverse interference obselved included pacemaker 
inhibition, p-tracldog ol electromagnetic noise, asynchronous activation, and 
inappropriate safety pacing. Pacemakers from only one manufacturer had 
electromagnetic filter and these pacemakers were not susceptible to in- 
tederence (0% - 0/28). Units from the other three rnanufaclurers without 
electromagnetic filters were susceptible to intederence (16.9% - 11165; 41% 
-- 23Lr~6; and 46°/= - 12/26). Pacemakers from the manufacturer which were 
resistant to interference were furifrer tested in vibo. Standard units with 
electromagnetic filters were contpared with the same units which had the 
filtration device removed. Two pacemakers studied in vitro with etsctmreag- 
uetic tilters were completely resistant to interference when exposed to digital 
telephones (0% interference) while two unfiltered evices were susceptible 
to interference to the same digital telephones (100% interference). 
Conclusion: Electromagnetic filters in pacemakers can provide protection 
from interference from digital cellular telephones. 
~ Decreased Acute Current Drain With Steroid 
FJuting High Impedance Pacing Leads: Results 
From a Multicenter Clinical Tdal 
Kenneth A. Ellenbegen, Mark A. Wood, David M. Gflligan, Matt Zmijewsld, 
and Capsure Z Clinical Investigators. Medical College Of Virginia and 
McGuire VAMC, Richmond, VA 
Increasing pacemaker pulse generator longevity by redudng pacing current 
drain is a desired goal of advances in lead technology. The sensing and 
pacing performance of a new small l~p Steroid e~utJog electrode (1.2 mn~ 
surface area, high impedance lead, HI) Medtronic Capsure Z leads atrial 
J 5534 and vantrieular 5034 was compared to that of a standard steroid 
eluting lead (5.8 mm 2 sudace area, control lead, (3) Medlmnic CapSure SP 
leads atrial J 5524 and ventricular 5024. A total of 305 patients received 
pairs of the control ead ((3, 5524/5024) and 190 patients received pairs of 
the high impedance lead (HI, 5534/5034) and were studied with respect to 
pacing capture thresholds (CT) measured at 2.5 Volts in ms, lead impedance 
(ohms) and sensing threshold (S, mV). Clinical charscteristice of the patient 
population were similar. These leads are compared at 3 months tollowiog 
implantation below: 
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